Formycon AG and Bioeq AG jointly announce an agreement with Sandoz AG for the commercialization of Epruvy in Germany. The Lucentis® 2biosimilar Epruvy® ("ranibizumab") is used to treat severe visual impairments such as neovascular ("wet") age-related macular degeneration ("nAMD") and other retinopathies. It is marketed by Sandoz in Germany under a license from Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV.
Approved by the European Medicines Agency EMA in September 2024, Epruvy® is available in a vial presentation and, in addition, as a pre-filled syringe, providing patients and healthcare professionals in Germany with a convenient and efficient treatment option. The innovative PFS technology has been specifically designed for intravitreal injections using a silicone-free device. The system addresses key safety aspects of this delicate ocular treatment, such as the elimination of silicone-oil related contamination, high dosing accuracy, combined with low injection pressure, which can minimize the risk of application errors.
The ready-to-use syringe reduces preparation time and supports efficient administration to patients with nAMD and other serious retinal diseases.
